Ixekizumab Halts Bone Damage in Axial Spondyloarthritis

TOPLINE: Ixekizumab reduced erosion and increased backfill in the sacroiliac joints of biologic disease-modifying antirheumatic drug (bDMARD)–naive patients with radiographic axial spondyloarthritis (r-axSpA) by week 16, with further improvements observed up to week 52. Male patients and human leukocyte antigen B27 (HLA-B27)–positive patients showed more pronounced structural changes…